Click here to load reader
Upload
syafiq-ali
View
1.210
Download
1
Embed Size (px)
DESCRIPTION
Taklimat berkenaan MERS-COV (Middle East Respiratory Syndrome-Corona Virus) berkenaan pengurusan sample yang diambil dari pesakit. Virus ini mula tersebar di Arab Saudi, dan perhatian lebih perlu diberikan kepada jemaah-jemaah yang baru pulang dari Umrah di Makkah & Madinah, Arab Saudi.
Citation preview
Pengurusan Sample Bagi Kes Jangkitan “Middle East Respiratory
Syndrome- Coronavirus” (Mers-CoV)
1
Ref:NIAID
• Background of the Virus
• Samples suitable for testing and WHO Guidelines
• Real time RT-PCR for Mers-CoV
• Main Hospitals and MKAK Sg Buloh and MKA Kota Kinabalu
Overview
Virus classification -RNA viruses
Middle East Respiratory Syndrome-Coronavirus (Mers-CoV)
First reported in June 2012, Saudi Arabia Coronaviridae Family, Genus Betacoronavirus (same as SARS-CoV). Positive sense, single stranded RNA virus About 26-32 Kb with “crown-like” feature
Transmission- Close Contact -aerosol (droplet), further investigation.
(SARS-CoV- “unique pathogenesis” as involved both upper and lower respiratory tract and gastro enteritis)
WHO Guidelines (27 June 2013)
Generally incubation period for cases of strong suspicion is less than 1 week
BUT in at least 1 case, known exposure occurred 9 to 12 days prior to onset of illness
Longer period of observation for contacts of cases
Incubation period may exceed 1 week but is less than 2 weeks
Source of Clinical Specimens
Hospitals
– Inpatients with severe Influenza
NO clinical specimens from outpatients and contacts!
Preferred Sample For Testing (WHO Guidelines, 27 June 2013)
Lower Respiratory Tract Sputum Endotracheal Aspirate Bronchoalveolar Lavage
If pt without signs and symptoms of lower respiratory tract infection and if lower respiratory tract specimen NOT Possible or Clinically Indicated
Both Nasopharyngeal and Oropharyngeal specimens should be collected
If initial testing of Nasopharyngeal swab is NEGATIVE BUT pt is Strongly Suspected of Mers-CoV, pt MUST be RE-TESTED using Lower Respiratory Tract Specimen
Others: tissue from biopsy/autopsy including lung, whole blood (in EDTA), paired serum for serology (4 weeks apart)
When to collect specimen
• As soon as possible after symptoms begin (24-72hrs)
• Best before antiviral medications are administered
Swabs
• Ideal – synthetic tip
• Specimens collected with swabs made of
calcium alginate, cotton or wooden sticks are NOT ACCEPTABLE (inhibit PCR)
Sample collection
Nasopharyngeal swab
Transport media
- Plain sterile bottles for aspirates and sputum
- VTM for swabs
- Plain tubes for paired sera
Viral Transport Media (VTM)
• Place swabs in sterile collection vials containing 1-2 ml of VTM
• Vials can be stored in a freezer at -20 oC until use
• Vials can be stored for short periods of time at 4 – 6oC
Storage and transport of specimens
• Transport to the laboratory as soon as possible
• Store specimens and transport at 4oC
• Store specimens at -70oC beyond 48 hours.
• If a -70°C freezer is not available, specimens should be kept at 4°C, preferably no longer than 4 days.
• Freezing at higher temperatures (e.g., -20°C) can reduce the likelihood of virus detection.
3 layer packaging
1
2
3
• Shipping clinical specimens:
- Clinical specimens should be shipped in ice (cold chain) in appropriate packaging
- All specimens should be labeled clearly and include information requested .
Transportation of Samples to Testing Facilities
Clinicians/Health care providers advised to wear appropriate PPE during sample taking from patients
All secretions should be placed in sterile bottle and ttransported on ice
All swabs must be placed in sterile tubes with sufficient VTM and transported on ice.
All samples must use “triple packaging” format with request forms before being transported to testing facilities
Issues
Laboratory Testing Methods
1. Real time RT-PCR (molecular lab)
2. Cell Culture
3. RT-PCR & Sequencing
4. Serology (paired sera 4 weeks apart)
Lower Respiratory Tract (Sputum, Endotracheal Aspirate, Bronchoalveolar Lavage)Other respiratory tract samples (Both Nasopharyngeal and oropharyngeal specimens), T/S
IMR will provide laboratory testing for these facilities until 01/08/2013
False Negative Results:
Samples NOT from Lower Respiratory Tract (request for fresh sample from lower respiratory
tract if HIGH disease suspicion index)
Poor quality of specimen/ PCR inhibition
Specimen was collected late or very early in the illness
The specimen was not handled or shipped appropriately
Quality Control of Testing during rRT-PCR
In the event of “positive results”, Samples should be referred to IMR for confirmation (sequencing)- only in INITIAL stage
IMR will provide Quality Assurance Programme for all testing facilities this year onwards for rRT-PCR Mers-CoV.
Briefing
Testing Procedures
List Of Facilities Trained To Perform rRT-PCR for Mers-CoV
1. Makmal Kesihatan Awam Kebangsaan, Sg Buloh2. Makmal Kesihatan Awam Kota Kinabalu3. Hospital Sungai Buloh4. Hospital Kuala Lumpur5. Hospital Umum Sarawak, Kuching6. Hospital Pulau Pinang7. Hospital Sultanah Aminah Johor Bahru8. Hospital Raja Permaisuri Bainun Ipoh9. Hospital HTAA, Kuantan10.Hospital Melaka11.Hospital HSNZ Kuala Trengganu12.Hospital HRPZ II Kota Bharu13.Hospital Sultanah Bahiyah Alor Setar14.Hospital Tuanku Jaafar Seremban
Tentative Start Date for Testing : 01/08/2013